Figure 5

PEG-ADI increases the efficacy of gemcitabine in vivo and is associated with abrogation of the gemcitabine-mediated induction of RRM2. A) Mice with MIA-PaCa-2 xenografts were treated with PBS, PEG-ADI (5 IU, weekly), gemcitabine (125 mg/kg, twice weekly) or combination of PEG-ADI and gemcitabine. Tumor volumes were measured on indicated days and reported as mean ± SD, B) Weight of MIA-PaCa-2 xenografts (* = p < 0.05 vs. PEG-ADI; ** = p < 0.05 vs. gemcitabine), C) Lysates of the MIA-PaCa-2 xenografts with immunoblotting for RRM2, dCK or cleaved caspase 3 following the treatments noted.